PI3K/AKT/mTOR inhibitory agents that have been studied in literature, such as rapamycin and everolimus, which both inhibit mTOR, are expected to lead to better therapeutic responses compared to traditional treatment modalities in primary breast cancers (22). Here, AKT1 is linked to breast cancer.